Dhanuka Agritech Ltd. Share Price

Dhanuka Agritech Ltd Company Fundamental Analysis

Dhanuka Agritech Ltd is an Indian agrochemical company engaged in manufacturing and marketing crop-protection products, including insecticides, herbicides, fungicides, bio-pesticides and plant growth regulators. The company has a strong distribution network of approximately 6,500 distributors and 80,000 retailers, reaching more than 10 million farmer touchpoints. It also collaborates with global agrochemical companies from Japan, the US and Europe to introduce new technologies and products in India. Q2 FY27 results, announced on 30 October 2026, showed a recovery in business performance. Revenue from operations increased 9.91% year-on-year to ₹657.51 crore, while EBITDA grew 11.88% to ₹152.97 crore. Net profit increased 16.24% to ₹109.22 crore, indicating improvement in operating profitability. However, H1 FY27 revenue declined marginally by 0.63% to ₹1,119.44 crore, and H1 net profit fell 2.64% to ₹145.53 crore. This suggests that the Q2 recovery is encouraging, but the overall first-half performance remains relatively subdued. Management has guided for low-single-digit revenue growth for FY27 and expects EBITDA margin pressure of approximately 125 basis points. At approximately ₹980 per share, Dhanuka Agritech had a market capitalisation of around ₹3,900–4,400 crore and a trailing P/E of approximately 14.5–16.5x, depending on the data source and earnings update. ROE is around 17–19%, ROCE approximately 22–24%, and debt-to-equity just 0.02, indicating a strong balance sheet. The company is also expanding its international presence following the acquisition of Bayer AG's fungicide brands, which could support export growth. Overall, Dhanuka Agritech has a strong distribution network, low debt and reasonable valuation, but its near-term growth remains dependent on agricultural demand and monsoon conditions. The Q2 recovery is positive, though sustained revenue and margin improvement over the coming quarters will be important.

See More

IIG PETROCHEMICALS FUNDAMENTAL RESEARCH REPORT

G Petrochemicals (NSE: IGPL, BSE: 500199), part of the Dhanuka group, is India’s largest maker of phthalic anhydride (PAN) ,with about half of the domestic market, fi ve PAN plants at one Taloja (Maharashtra) complex, and by its own account thelowest cost of production in the industry. It is also India’s only maker of maleic anhydride (MAN), which it recovers from PANwash water, and it makes benzoic acid and di-ethyl phthalate (DEP). PAN goes into plasticisers, paints (alkyd resins),unsaturated polyester resins and pigments. Most customers are within 150-200 km of the plant. Rated IND AA-/Stable . Event 1 - the cycle turned in Q1 FY27. After a near-zero FY26 (consolidated PAT Rs 2 Cr; standalone Rs 23 Cr, after inventorylosses and weak spreads), Q1 FY27 standalone revenue was Rs 625 Cr (+30%) , EBITDA Rs 120 Cr (19.2% margin vs 2.7%) andPAT Rs 71 Cr (consolidated Rs 66 Cr). The gain came from price, not volume: the Middle-East confl ict lifted ortho-xylene andPAN prices 30-40%, and volume was 10-15% lower than in Q4. Management puts the market spread at $250-300/t (10-yearaverage $200-250) and says IGPL earns about $100-120/t more through yield and by-products. About Rs 10-15 Cr of Q1 waslow-cost inventory sold at high prices. Event 2 - protection renewed.

See More

Orchid Pharma Limited Latest Updates

$178 Million Exblifep Licensing Deal in Russia On July 8, 2026, Orchid Pharma executed an exclusive licensing agreement with Russian pharmaceutical major Pharmasyntez JSC for its patented hospital antibiotic Exblifep. Under the deal, Pharmasyntez holds exclusive registration and marketing rights across Russia, while Orchid retains sole manufacturing and supply mandates. Pending Russian health ministry clearance, the partnership is projected to deliver cumulative revenues of $178 million over a 10-year horizon. Final NCLT Clearance for Dhanuka Laboratories Merger In June 2026, the National Company Law Tribunal (NCLT) issued a formal order sanctioning the amalgamation of promoter entity Dhanuka Laboratories Limited into Orchid Pharma Limited. Backdated to April 1, 2024, the structural merger consolidates product portfolios and API research assets, with management targeting combined annual revenues of ₹1,400–1,500 crore and EBITDA of ₹200–250 crore. FY26 Financial Summary For the fourth quarter ended March 31, 2026 (Q4 FY26), consolidated total income grew 15.1% quarter-on-quarter to ₹244.95 crore, while net profit (PAT) recovered to ₹23.78 crore. On a full-year basis, operating EBITDA margins faced mild headwinds due to elevated raw material prices across core cephalosporin bulk drug supply chains. SEBI Compliance Window In strict compliance with SEBI LODR and Insider Trading regulations, the company executed the formal closure of its internal trading window for all designated insider groups and connected persons on June 30, 2026. The trading restriction remains fully active pending the formal board adoption and presentation of the upcoming Q1 FY27 financial results.

See More

Orchid Pharma–Dhanuka Merger Creates ₹1,500 Cr Pharma Giant

Key Highlights Merger Approval: NCLT clears merger of Dhanuka Laboratories with Orchid Pharma. Revenue Potential: Combined entity expected to generate ₹1,400–1,500 crore revenue. EBITDA Outlook: EBITDA projected at ₹200–250 crore. Synergies: Operational efficiencies, cost savings, and stronger market presence. 📊 Financial Snapshot (Post-Merger Estimates) Metric Value Implication Revenue ₹1,400–1,500 Cr Strong topline growth. EBITDA ₹200–250 Cr Margin expansion potential. EBITDA Margin ~15–17% Healthy profitability. Debt Position Moderate Manageable leverage post-merger. ROCE ~12–14% Improved capital efficiency. ROE ~10–12% Stronger shareholder returns. ⚡ Growth Drivers Integrated operations → cost savings and efficiency. Expanded product portfolio → stronger domestic & export presence. Synergies in R&D and manufacturing. Enhanced scale → better bargaining power and market positioning. ⚠️ Risks Integration challenges between Orchid and Dhanuka. Regulatory hurdles in pharma approvals. Competitive pressures from larger peers (Sun Pharma, Dr. Reddy’s, Cipla). The merger positions Orchid Pharma as a mid-sized integrated pharma player with stronger fundamentals, improved margins, and enhanced market presence.

See More

Dhanuka Agritech Announces ₹70 Cr Share Buyback

💰

has announced a share buyback of 5,00,000 equity shares at ₹1,400 per share, aggregating to ₹70 crore. The buyback offer opens on June 4, 2026, providing an opportunity for eligible shareholders to participate.

See More